You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020216024
Dec 20204006
Jan 202184021
Feb 202172018
Mar 2021122022
Apr 202150013
May 202119015
Jun 20210014
Jul 20210019
Aug 20210010
Sep 2021005
Oct 202164028
Nov 202184018
Dec 202154015
Jan 202244010
Feb 20222408
Mar 20222007
Apr 202250011
May 20222608
Jun 202244010
Jul 20223204
Aug 202230010
Sep 202214010
Oct 20222206
Nov 20222606
Dec 20223806
Jan 20233008
Feb 20231800
Mar 20231807
Apr 202320011
May 20231800
Jun 20233403
Jul 20231806
Aug 20231806
Sep 20231203
Oct 20231809
Nov 20234403
Dec 20233602
Jan 20241400
Feb 20243403
Mar 20243202
Apr 20241603
May 20243402
Jun 20243602
Jul 20243406
Aug 20244408
Sep 20243004
Oct 202444014
Nov 202452013
Dec 202468013
Jan 202556024
Feb 2025807
Mar 20250011
Apr 2025005
May 2025006
Jun 2025008
Total19610513